Posters

Characterising keratoconus in the Omani population: an experience from Armed Forces Hospital in Muscat

Poster Details

First Author: H. Al-Mahrouqi OMAN

Co Author(s): N. Al-Shamli   N. Raj Mohan   S. Bani Oraba   A. Al-Raisi           

Abstract Details

Purpose:

Keratoconus is a relatively prevalent disease in the Middle East. Despite this and observations made from various ophthalmic clinics in Oman regarding its common presentation, there is paucity of statistical data on keratoconus in the Omani population. This hospital based study aims to ascertain the incidence, severity and associated risk factors of Omani keratoconus patients.

Setting:

Ophthalmology Department, Armed Forces Hospital (AFH), Muscat, The Sultanate of Oman.

Methods:

All new Omani keratoconus patients presenting to Armed Forces Hospital in Muscat over a five year period (2011-2015) were included. Patients medical records were retrospectively reviewed to note the demographics, family history, ocular allergy, vision (in LogMAR) and refraction, topography, pachymetry and the various treatment modalities received.

Results:

There were 458 new keratoconus patients (275 males, 201 females) comprising a total of 893 eyes with a mean age of 20 years (Range 6-46 years). More than one third of the patients reported family history of keratoconus and 89% used anti-allergic eyedrops. About a third of eyes with no prior treatment already showed advanced disease on presentation (K value >53, Central corneal thickness <450um and best corrected spectacle visual acuity of less than 0.5). A lower age at diagnosis correlated with more severe keratoconus. Fortunately rigid contact lenses improved vision to better than 0.1 for most patients.

Conclusions:

Keratoconus is a common disease seen in AFH with most patients being at the university age and many presenting with already advanced disease and significant visual disability. Population-based studies are an important next step and prevention strategies and timely interventions to limit the burden of the disease are crucial.

Financial Disclosure:

None